These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 15054877

  • 1. Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.
    D'Alessio S, Margheri F, Pucci M, Del Rosso A, Monia BP, Bologna M, Leonetti C, Scarsella M, Zupi G, Fibbi G, Del Rosso M.
    Int J Cancer; 2004 May 20; 110(1):125-33. PubMed ID: 15054877
    [Abstract] [Full Text] [Related]

  • 2. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.
    Margheri F, D'Alessio S, Serratí S, Pucci M, Annunziato F, Cosmi L, Liotta F, Angeli R, Angelucci A, Gravina GL, Rucci N, Bologna M, Teti A, Monia B, Fibbi G, Del Rosso M.
    Gene Ther; 2005 Apr 20; 12(8):702-14. PubMed ID: 15674398
    [Abstract] [Full Text] [Related]

  • 3. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
    Nip J, Rabbani SA, Shibata HR, Brodt P.
    J Clin Invest; 1995 May 20; 95(5):2096-103. PubMed ID: 7537755
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines.
    Lakka SS, Rajagopal R, Rajan MK, Mohan PM, Adachi Y, Dinh DH, Olivero WC, Gujrati M, Ali-Osman F, Roth JA, Yung WK, Kyritsis AP, Rao JS.
    Clin Cancer Res; 2001 Apr 20; 7(4):1087-93. PubMed ID: 11309361
    [Abstract] [Full Text] [Related]

  • 5. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.
    Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS.
    Int J Oncol; 2007 Jul 20; 31(1):5-17. PubMed ID: 17549400
    [Abstract] [Full Text] [Related]

  • 6. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS.
    J Biol Chem; 2005 Oct 28; 280(43):36529-40. PubMed ID: 16127174
    [Abstract] [Full Text] [Related]

  • 7. [Antisense RNA for urokinase receptor inhibits the invasiveness and metastasis of lung carcinoma].
    Liao J, Xu S, Tang H, Lian F, Zhu Y.
    Zhonghua Bing Li Xue Za Zhi; 2001 Oct 28; 30(5):357-60. PubMed ID: 11769733
    [Abstract] [Full Text] [Related]

  • 8. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A, Kassis J, Kharait S, Kloeker S, Manos E, Jones DA, Wells A.
    Exp Cell Res; 2004 Sep 10; 299(1):91-100. PubMed ID: 15302576
    [Abstract] [Full Text] [Related]

  • 9. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
    Bryan L, Paugh BS, Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, Milstien S, Spiegel S, Kordula T.
    Mol Cancer Res; 2008 Sep 10; 6(9):1469-77. PubMed ID: 18819934
    [Abstract] [Full Text] [Related]

  • 10. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH, Mazar A, Henkin J, Rabbani SA.
    Cancer Res; 1997 Aug 15; 57(16):3585-93. PubMed ID: 9270032
    [Abstract] [Full Text] [Related]

  • 11. bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.
    Trisciuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U, Zupi G, Del Bufalo D.
    J Biol Chem; 2004 Feb 20; 279(8):6737-45. PubMed ID: 14660675
    [Abstract] [Full Text] [Related]

  • 12. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM.
    Cancer Res; 2005 Sep 01; 65(17):7775-81. PubMed ID: 16140945
    [Abstract] [Full Text] [Related]

  • 13. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S, New L, Pan Z, Han J, Nemerow GR.
    J Biol Chem; 2000 Apr 21; 275(16):12266-72. PubMed ID: 10766865
    [Abstract] [Full Text] [Related]

  • 14. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
    Yang JL, Seetoo Dq, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ.
    Int J Cancer; 2000 Sep 20; 89(5):431-9. PubMed ID: 11008205
    [Abstract] [Full Text] [Related]

  • 15. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F, Jia S, Xing G, Gao L, Zhang L, He F.
    DNA Cell Biol; 2001 May 20; 20(5):297-305. PubMed ID: 11410166
    [Abstract] [Full Text] [Related]

  • 16. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
    Khatib AM, Nip J, Fallavollita L, Lehmann M, Jensen G, Brodt P.
    Int J Cancer; 2001 Feb 01; 91(3):300-8. PubMed ID: 11169951
    [Abstract] [Full Text] [Related]

  • 17. [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].
    Chen XJ, Zheng W, Chen LL, Chen ZB, Wang SQ.
    Zhonghua Yi Xue Za Zhi; 2004 Oct 17; 84(20):1721-5. PubMed ID: 15569435
    [Abstract] [Full Text] [Related]

  • 18. Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas.
    Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Tung CH, Weissleder R, Rao JS.
    Cancer Res; 2004 Jun 15; 64(12):4069-77. PubMed ID: 15205313
    [Abstract] [Full Text] [Related]

  • 19. Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
    Krishnamoorthy B, Darnay B, Aggarwal B, Dinh DH, Kouraklis G, Olivero WC, Gujrati M, Rao JS.
    Clin Cancer Res; 2001 Dec 15; 7(12):4195-201. PubMed ID: 11751520
    [Abstract] [Full Text] [Related]

  • 20. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.
    Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R, Rao JS.
    Oncogene; 1997 Mar 20; 14(11):1351-9. PubMed ID: 9178895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.